fashion -WSS

fashion

author：knowledge 2025-09-06 04:13:09 - browse：92

Scientist walks up a strand of DNA -- First Opinion coverage from STAT — Adobe

Eli Lilly said Tuesday that it will pay $200 million to gene-editing firm Beam Therapeutics for Beam’s stake in Verve Therapeutics, another gene-editing company focused on treatments for heart disease.

The deal, which also includes future milestone payments, is evidence that despite the pressure on biotechnology stocks there is still interest in very early cutting-edge technologies among big pharmaceutical players. It also provides Beam, which announced on Oct. 19 that it would cut 100 jobs, or 20% of its workforce, to save cash, a large infusion of money.

“This is like a true win-win-win deal, which is rare in this business, but it’s really, really exciting to see,” said John Evans, Beam’s CEO, in an interview with STAT.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Why hospitals are withdrawing from US News rankings

Wikipedia

WSS

Why hospitals are withdrawing from US News rankings

How dance can help nurses traumatized by Covid

Startup Neumora takes a novel depression drug to Phase 3

STAT Virtual Event: The State of Biosimilars: What to Watch

Custom gene therapy hints at new path for rare disease treatments

Colonoscopy at 40? Study finds a possible benefit

explore

fashion

hotspot

BioMarin wins approval for gene therapy to treat hemophilia A

The battle over the Brookhaven Landfill on Long Island

Tori Bowie and the unacceptable rates of Black maternal death

How dance can help nurses traumatized by Covid

New air purifier tech could be key to improving indoor air quality

Ask STAT: What do you want to know about ChatGPT in medicine?

How to save PrEP access — and even expand it

Do masks work? RCTs can't tell us

At least 13 dead in Texas as scorching temps continue

Weight bias in eating disorder treatment complicated by new weight loss drugs

explore

Colonoscopy at 40? Study finds a possible benefit

STAT Virtual Event: The State of Biosimilars: What to Watch

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

Disclosing genetic information: not as worrisome as once feared

As digital health tech proliferates, a new institute aims to cut through hype

Why are elite athletes different? Take a look at their microbes

Wikipedia

focus

leisure time

entertainment